Arjun Mittra, MD
Academic Title: Assistant Professor in the College of Medicine
Research Program: Translational Therapeutics
About Me
More info forI am an assistant professor in the Division of Medical Oncology at the OSUCCC – James. I specialize in treating patients with cancers of the gastrointestinal (GI) tract, specifically cancers of the pancreas, bile ducts, stomach, esophagus, colon, rectum and liver. Before joining The James, I completed fellowships in hematology/oncology at the Mayo Clinic in Jacksonville, Florida, and in developmental therapeutics at the National Cancer Institute in Bethesda, Maryland. As a member of the Translational Therapeutics Program at the OSUCCC – James, my research focuses on the development of novel cancer therapeutics for solid tumors through early-phase clinical trials. I am particularly interested in developing biomarker-driven clinical trials for solid tumors, especially those of the GI tract. The James is an institution with a traditionally strong infrastructure to support basic, translational and clinical research as an NCI-designated comprehensive cancer center, and this provides the perfect environment for developing and conducting trials that bring new therapies and technologies to our patients. I particularly enjoy the multidisciplinary approach to cancer care, as it allows me to work alongside colleagues from different disciplines to ensure that we are treating the whole patient with an individualized treatment plan that’s been tailored specifically for their needs. It’s this team approach that makes The James such a rewarding place to work as we strive to achieve our goal of a cancer-free world.
Clinical Expertise
More info for- Stomach Cancers
- Colon Cancers
- Small Intestine Cancer
- Liver Cancers
- Pancreatic Cancers
- Gallbladder Cancers
- Gastrointestinal Cancers
- Rectal Cancers
- Anal Gland Cancer
- Anal Cancers
- Esophageal Cancers
Where I See Patients
More info forEducation & Training
More info forFellowship - Hematology & Oncology
- Mayo Clinic Jacksonville
4500 San Pablo Rd S, Jacksonville, FL
Fellowship - Hematology & Oncology
- National Cancer Institute, NIH
9000 Rockville Pike, Bethesda, MD
Medical School
- Terna Medical College
Sector 12, Phase II, Navi Mumbai
Residency - Internal Medicine
- Texas Health Presbyterian Hospital of Dallas
8200 Walnut Hill Ln, Dallas, TX
- Mayo Clinic Jacksonville
Academic Office & Contact Information
More info forAcademic Office:
Lincoln Tower 1335
1800 Cannon Dr
Columbus, Ohio 43210Email:
Arjun.Mittra@osumc.eduReviews
More info forPatient Satisfaction Review
The overall patient satisfaction rating is an average of all patient responses to the five questions gathered from the Outpatient Oncology survey, developed by Press Ganey Associates for use in oncology clinics across the country. On behalf of The James, Press Ganey administers the survey to patients who see our providers in an outpatient clinic office. For additional information about the patient satisfaction survey, please visit our
Patient Satisfaction Survey page The comments are submitted by patients and reflect their view and opinions. The comments are not endorsed by and do not necessarily reflect the views of The James.
Publications
More info forAugust 20, 2024Mature MUC5AC Expression in Resected Pancreatic Ductal Adenocarcinoma Predicts Treatment Response and Outcomes.
Manne A, Esnakula A, Sheel A, Sara A, Manne U, Paluri RK, He K, Yang W, Sohal D, Kasi A, Noonan AM, Mittra A, Hays J, Roychowdhury S, Malalur P, Rahman S, Jin N, Cloyd JM, Tsai S, Ejaz A, Pitter K, Miller E, Thanikachalam K, Dillhoff M, Yu L
Int J Mol Sci
April 5, 2024Real-World Multicenter Study of PD-1 Blockade in HIV-Associated Classical Hodgkin Lymphoma Across the United States.
Lurain K, Zarif TE, Ramaswami R, Nassar AH, Adib E, Abdel-Wahab N, Chintapally N, Drolen CE, Feldman T, Haykal T, Nebhan CA, Kambhampati S, Li M, Mittra A, Lorentsen M, Kim C, Drakaki A, Morse M, Johnson DB, Mangla A, Dittus C, Ravi P, Baiocchi RA, Chiao EY, Rubinstein PG, Yellapragada SV, LaCasce AS, Sonpavde GP, Naqash AR, Herrera AF
Clin Lymphoma Myeloma Leuk
November 27, 2023Pharmacodynamic effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumors.
Mittra A, Coyne GHOS, Zlott J, Kummar S, Meehan R, Rubinstein L, Juwara L, Wilsker D, Ji J, Miller B, Navas T, Ferry-Galow KV, Voth AR, Chang TC, Jiwani S, Parchment RE, Doroshow JH, Chen AP
Cancer Chemother Pharmacol
August 11, 2023Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors.
El Zarif T, Nassar AH, Pond GR, Zhuang TZ, Master V, Nazha B, Niglio S, Simon N, Hahn AW, Pettaway CA, Tu SM, Abdel-Wahab N, Velev M, Flippot R, Buti S, Maruzzo M, Mittra A, Gheeya J, Yang Y, Rodriguez PA, Castellano D, de Velasco G, Roviello G, Antonuzzo L, McKay RR, Vincenzi B, Cortellini A, Hui G, Drakaki A, Glover M, Khaki AR, El-Am E, Adra N, Mouhieddine TH, Patel V, Piedra A, Gernone A, Davis NB, Matthews H, Harrison MR, Kanesvaran R, Giudice GC, Barata P, Farolfi A, Lee JL, Milowsky MI, Stahlfeld C, Appleman L, Kim JW, Freeman D, Choueiri TK, Spiess PE, Necchi A, Apolo AB, Sonpavde GP
J Natl Cancer Inst
May 16, 2023Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium.
El Zarif T, Nassar AH, Adib E, Fitzgerald BG, Huang J, Mouhieddine TH, Rubinstein PG, Nonato T, McKay RR, Li M, Mittra A, Owen DH, Baiocchi RA, Lorentsen M, Dittus C, Dizman N, Falohun A, Abdel-Wahab N, Diab A, Bankapur A, Reed A, Kim C, Arora A, Shah NJ, El-Am E, Kozaily E, Abdallah W, Al-Hader A, Abu Ghazal B, Saeed A, Drolen C, Lechner MG, Drakaki A, Baena J, Nebhan CA, Haykal T, Morse MA, Cortellini A, Pinato DJ, Dalla Pria A, Hall E, Bakalov V, Bahary N, Rajkumar A, Mangla A, Shah V, Singh P, Aboubakar Nana F, Lopetegui-Lia N, Dima D, Dobbs RW, Funchain P, Saleem R, Woodford R, Long GV, Menzies AM, Genova C, Barletta G, Puri S, Florou V, Idossa D, Saponara M, Queirolo P, Lamberti G, Addeo A, Bersanelli M, Freeman D, Xie W, Reid EG, Chiao EY, Sharon E, Johnson DB, Ramaswami R, Bower M, Emu B, Marron TU, Choueiri TK, Baden LR, Lurain K, Sonpavde GP, Naqash AR
J Clin Oncol
December 22, 2022Stereotactic Body Radiation Therapy (SBRT) Plus Immune Checkpoint Inhibitors (ICI) in Hepatocellular Carcinoma and Cholangiocarcinoma.
Jiang J, Diaz DA, Nuguru SP, Mittra A, Manne A
Cancers (Basel)
December 20, 2022BCL-xL inhibition potentiates cancer therapies by redirecting the outcome of p53 activation from senescence to apoptosis.
Bharti V, Watkins R, Kumar A, Shattuck-Brandt RL, Mossing A, Mittra A, Shen C, Tsung A, Davies AE, Hanel W, Reneau JC, Chung C, Sizemore GM, Richmond A, Weiss VL, Vilgelm AE
Adv Psychosom Med
August 16, 2021Outcomes of pregnancy during immunotherapy treatment for cancer: Analysis of clinical trials sponsored by the National Cancer Institute.
Mittra A, Naqash AR, Murray JH, Finnigan S, Kwak-Kim J, Ivy SP, Chen AP, Sharon E
Oncologist
April 16, 2021Safety, anti-tumor activity, and biomarker analysis in a phase 1 trial of the once-daily Wee1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors.
Takebe N, Naqash AR, O'Sullivan Coyne G, Kummar S, Do KT, Bruns A, Juwara L, Zlott J, Rubinstein L, Piekarz RL, Sharon E, Streicher H, Mittra A, Miller SB, Ji J, Wilsker DF, Kinders RJ, Parchment RE, Chen L, Chang TC, Das B, Mugundu G, Doroshow JH, Chen AP
Clin Cancer Res
January 1, 2021Biliary Tract Cancers: Treatment Updates and Future Directions in the Era of Precision Medicine and Immuno-Oncology.
Manne A, Woods E, Tsung A, Mittra A
Front Oncol
Consulting and Related Relationships
More info forAt The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the university requires annual disclosures from all faculty members with external interests related to their university responsibilities. As of 09/30/2024, Dr. Mittra has reported no relationships with companies or entities.
Patient Comments
Dr. Mittra and his team made me feel very comfortable and confident in their care of me.
Dr. Mittra and staff are very friendly and efficient and always helpful to see that your concerns are met with compassion and professionalism.
Doctor and staff very professional
Good
Good
Dr Mittra is one of the best around. Great bedside manner and takes his time to explain things. Thank you Dr Mittra and staff. Exceptional provider
Dr Mittra is the best oncologist I have ever met (I worked at a hospital for 30yrs) I would recommend him to everyone he has great bedside manors I love his knowledge he always includes me prior to making decisions he keeps me updated on everything regardless of how small or big something is. I respect him and the decisions we make
Dr Mittra is knowledgeable and helpful.
Dr Mittra answered all our questions and gave us time to process what he was telling us.
Ist appointment oncologist I only saw once, as he was leaving the James@OSU. I am extremely pleased with Dr. Mitra and his nursing staff.
Good
Exceptional care
Could not be happier with my care giver Very educational!!
I would not be here without Dr. MITTRA, Dr.Miller & Dr.TSUNG. THEY WENT ABOVE &beyond finding and executing the Clinical Trial. I was a couple of months from being gone.They never gave up.Sense saving my life from a form and position of the Cancer is almost always fatal. I am living a normal life.....this trial & team are truly a miracle. We think of them like family.
Good
Excellent. Completely trust this Doctor
Outstanding medical staff. Compassionate and patient.
Not clean on how or why treatment decisions were made.
Dr. Mittra was very caring, offered advice on treatment and answered all questions
Dr. Mittra & Mandy Wagner continue to go above and beyond every time I see them.
Just waiting to see them is time consuming.